乳腺癌患者血浆多药耐药基因相关蛋白P-gp活性分析及其临床应用  

Investigation and its clinical significance of the relative activity of multidrug resistance P-glycoprotein in the plasma of breast cancer patients

作　　者：田学智[1] 郭爱芝[1] 乔丽娟[3] 许慧娟[2] 

机构地区：[1]山西省肿瘤医院检验科,太原030013 [2]山西省肿瘤医院乳腺中心,太原030013 [3]山西省肿瘤研究所免疫室,太原030013

出　　处：《肿瘤研究与临床》2009年第7期463-465,共3页Cancer Research and Clinic

摘　　要：目的探讨乳腺癌患者治疗过程中血浆样本中多药耐药基因（mdr-1）相关的磷-糖蛋白（P—gp）的变化，为临床治疗提供参考依据。方法采用生化反应方法，将血浆样本与化学试剂混匀，根据反应前后透光率的不同，计算每个样本P—gp活性的改变以及对长春新碱的相对活性，相对活性大于30％即判定为P—gp阳性。结果治疗前P—gp阳性率为16．2％，化疗3个周期后P—gp阳性率为43．2％，二者差异有统计学意义（P〈0．05）。治疗前和化疗后P—gp阳性有淋巴结转移的分别为5／6和9／16，无淋巴结转移的分别为1／6和7／16。结论乳腺癌患者血浆P—gp活性测定，对乳腺癌化疗用药选择及其预后判断具有参考价值。Objective To investigate the relative activity of muhidrug resistance P-glycoprotein in the plasma of breast cancer patients, analyze the expression of P-glycoprotein before and after chemotherapy and evaluate its clinical value. Methods The plasma of patients and chemical reagents were mixed and distributed into the 96-well plate. The plate was read at 340 nm absorbance before and after reaction. The variation of absorbanee for each well was calculated, and then relative activity of each sample was compared to the referent compound activity. The relative activity of over 30 % was taken as positive expression of the P- gp for each sample. Results The frequency of P-glycoprotein expression was significantly increased from 16.2 % before chemotherapy to 43.2 % after chemotherapy （P 〈0.05）. The positive expression of P- glycoprotein before and after chemotherapy were 5/6 and 9/16, respectively, in patients with positive lymph node metastasis, and 1/6 and 7/16, respectively, in patients with negative lymph node metastasis. Conclusion The results of this preliminary study suggest in P-glycoprotein expression in plasma of patients play an important role in the selection of drugs, which may be useful to evaluate the prognosis for treatment of breast cancer patients.

关 键 词：乳腺肿瘤 基因 MDR P糖蛋白 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]